Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Axon Enterprise Inc (AXON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Axon Enterprise Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Axon Enterprise Inc trades at $600.05 (market cap $51.62B). The key difference: Axon Enterprise Inc is far larger — about 11.5× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Axon Enterprise Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | AXON | |
|---|---|---|
Market Cap | $4.49B | $51.62B |
Sector | Health | Technology |
52-Week High | $28.06 | $870.97 |
52-Week Low | $20.06 | $345.94 |
Enterprise Value | $3.69B | $52.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Axon Enterprise (AXON) trades at $622.20, up 4.21% today, with strong technical momentum as it crosses above key moving averages. The stock shows robust revenue growth, reaching $2.78 billion in 2025, though valuation ratios like a P/E of 250.95 appear elevated. Recent news highlights FAA drone defense approvals and CEO focus on non-lethal public safety technology, driving positive sentiment.
Outlook remains positive with an 80.95% analyst buy rating and $661.50 consensus price target, but risks include high valuation sensitivity and mixed earnings beats. Growth in software services and international expansion offer upside, while cash flow volatility and competitive pressures require monitoring for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Axon Enterprise Inc
Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.
Read more on AXON →
